Several other hedge funds and other institutional investors also recently made changes to their positions in the business. GAMMA Investing LLC boosted its stake in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after purchasing an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after purchasing an additional 1,507 shares in the last quarter. Quarry LP boosted its position in shares of Roivant Sciences by 50.0% during the third quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after buying an additional 2,500 shares during the last quarter. Blue Trust Inc. grew its holdings in Roivant Sciences by 550.1% during the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock worth $91,000 after buying an additional 6,667 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new stake in Roivant Sciences in the 4th quarter valued at $121,000. 64.76% of the stock is owned by institutional investors.

ROIV opened at $10.83 on Tuesday. The firm has a market cap of $7.73 billion, a P/E ratio of -72.20 and a beta of 1.26. Roivant Sciences Ltd. has a fifty-two week low of $9.93 and a fifty-two week high of $13.06. The firm has a 50-day moving average of $10.79 and a 200 day moving average of $11.45.

Roivant Sciences (NASDAQ:ROIV – Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities research analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

In related news, CIO Mayukh Sukhatme sold 689,495 shares of the business’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.01, for a total value of $8,280,834.95. Following the sale, the executive now directly owns 18,836,547 shares in the company, valued at approximately $226,226,929.47. The trade was a 3.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Eric Venker sold 177,704 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16. Following the sale, the chief operating officer now directly owns 740,976 shares in the company, valued at approximately $8,550,863.04. This trade represents a 19.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,439,640 shares of company stock worth $27,451,035 over the last ninety days. 7.90% of the stock is currently owned by company insiders.

Several analysts have recently issued reports on ROIV shares. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Roivant Sciences has a consensus rating of “Buy” and a consensus price target of $18.08.

Check Out Our Latest Stock Report on Roivant Sciences

(Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report).

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.